Atara Biotherapeutics (Nasdaq:ATRA) is a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Originating from over a...
Atara Biotherapeutics (Nasdaq:ATRA) is a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Originating from over a decade of groundbreaking clinical experience at Memorial Sloan Kettering and QIMR Berghofer, Atara's off-the-shelf, or allogeneic, T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's most advanced T-cell immunotherapy in development, tabelecleucel (formerly known as ATA129), is being developed for the treatment of patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC). Off-the-shelf ATA188 and autologous ATA190, the Company's T-cell immunotherapies using a complementary targeted antigen recognition technology, target specific EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS). Working at Atara Atara is a 180+ person publicly traded (Nasdaq: ATRA) clinical-stage biotechnology company. We are co-located by design in Westlake Village, CA (northwest LA) and South San Francisco, CA, with a process development lab in the Denver, CO area and an office in New York City. We are also constructing a ~90,000 sq. ft. multi-product manufacturing and R&D facility in Thousand Oaks, CA that will bring together all our southern CA employees and operations. People at Atara are high integrity, collaborative, roll-up-your-sleeves types who are deeply committed to putting patients first and advancing medical care with demonstrated urgency. With many accomplished people at Atara, we share humility, flexibility, respect, teamwork, good judgment and being practical in our approach to advance our therapies. We each enjoy in the journey of advancing cutting edge programs, while responsibly teaching and learning together along the way. T-Cell Immunotherapy Peer Companies Kite Pharma Juno Therapeutics Bluebird bio Adaptimmune Therapeutics Cellectis SA Bellicum Pharmaceuticals